Kyverna Therapeutics, Inc.
NASDAQ:KYTXBiotechnology
-$0.12 today
- Market cap
- $283.23M
- Beta
- 1.96
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$2.59
Volume 1.05M
Average 0.94M
KYTX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Kyverna Therapeutics, Inc.NASDAQ: KYTX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $29.72M fell 20.6% year over year, behind the -0.7% change in trailing-twelve-month research & development. Sequentially, it fell 1.0% from the prior quarter. Over 3 fiscal years it compounded at +67.6% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -20.6% toward the trailing-twelve-month pace of -0.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 133.72M USD
- Year-over-year change
- +18.9%
- 4-year CAGR
- +50.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 133.72M | +18.9% |
| FY2024 | 2024-12-31 | 112.47M | +133.3% |
| FY2023 | 2023-12-31 | 48.22M | +69.8% |
| FY2022 | 2022-12-31 | 28.4M | +9.9% |
| FY2021 | 2021-12-31 | 25.85M | — |
Research & Development vs competitors
How KYTX compares with its peers on the latest reported figures
- KYTX's LTM Mar 2026 research & development of $126.01M is the 5th highest of the 11 companies compared; the peer median is $79.55M.
- Its year-over-year change of -0.7% is the 5th highest of 10, against a peer median of -11.7%.
- Over three fiscal years its annual growth of +67.6% compares with a peer median of +13.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $159.57M | +37.4% | +18.6% | — | |
| LTM Mar 2026 | $151.83M | -11.7% | -0.1% | 489780.6% | |
| LTM Mar 2026 | $151.01M | +44.8% | +53.7% | — | |
| LTM Mar 2026 | $129.09M | -32.1% | -16.3% | — | |
| LTM Mar 2026 | $126.01M | -0.7% | +67.6% | — | |
| LTM Mar 2026 | $92.92M | +60.8% | +57.0% | — | |
| LTM Mar 2026 | $66.19M | -62.3% | -19.9% | 171.1% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $62.33M | -17.5% | +9.1% | — |
| LTM Mar 2026 | $61.84M | — | +24.0% | 6710.8% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $49.38M | +11.3% | +45.0% | — |
| LTM Mar 2026 | $18.13M | -12.8% | -16.7% | 3625.8% | |
| Peer median (excluding KYTX) | $79.55M | -11.7% | +13.8% | 5168.3% | |
Competitors are the stored peer set for KYTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.66M | 7.03M | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 1.71M | 2.13M | 0 |
| Gross Profit | 5.66M | 7.03M | (1.71M) | (2.13M) | 0 |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| Research & Development | 25.85M | 28.4M | 48.22M | 112.47M | 133.72M |
| Selling, General & Admin | 6.15M | 8.01M | 12.48M | 30.13M | 36.11M |
| Operating Expenses | 32M | 36.41M | 60.7M | 140.47M | 169.83M |
| Depreciation & Amortization | 586K | 1.05M | 1.71M | 2.13M | 1.8M |
| EBITDA | (25.76M) | (27.78M) | (58.47M) | (125.2M) | (159.02M) |
| EBITDA Margin | -455.5% | -395.4% | — | — | — |
| Operating Income | (26.35M) | (29.38M) | (62.41M) | (142.6M) | (169.83M) |
| Operating Margin | -465.8% | -418.3% | — | — | — |
| Interest Income | 1K | 565K | 2.28M | 15.36M | 9.09M |
| Interest Expense | 3K | 65K | 187K | 142K | 489K |
| Other Income / Expenses | (4K) | 491K | 2.04M | 15.13M | 8.52M |
| Income Before Tax | (26.35M) | (28.89M) | (60.37M) | (127.48M) | (161.31M) |
| Pre-Tax Margin | -465.9% | -411.3% | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.35M) | (28.89M) | (60.37M) | (127.48M) | (161.31M) |
| Net Margin | -465.9% | -411.3% | — | — | — |
| EPS (Basic) | (1.02) | (1.12) | (0.00) | (3.33) | (3.64) |
| EPS (Diluted) | (1.02) | (1.12) | (0.00) | (3.33) | (3.64) |
| Weighted Avg Shares | 25.8M | 25.8M | 673.62M | 38.33M | 44.26M |
| Weighted Avg Shares (Diluted) | 25.8M | 25.8M | 673.62M | 38.33M | 44.26M |
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
Intrinsic Alpha fair value
Locked
Current Price
$4.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.